176 related articles for article (PubMed ID: 18437502)
21. Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma.
Petrilli AS; Kechichian R; Broniscer A; Garcia RJ; Tanaka C; Francisco J; Lederman H; Odone Filho V; Camargo OP; Bruniera P; Pericles P; Consentino E; Ortega JA
Med Pediatr Oncol; 1999 Aug; 33(2):71-5. PubMed ID: 10398179
[TBL] [Abstract][Full Text] [Related]
22. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
[TBL] [Abstract][Full Text] [Related]
23. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
[TBL] [Abstract][Full Text] [Related]
24. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy response analysis for osteosarcom with intra-arterial chemotherapy by subcutaneous implantable delivery system.
Li D; Cui Q; Liu Y; Wang X; Liu C; Liu S; Zeng Y
Pathol Oncol Res; 2011 Dec; 17(4):947-53. PubMed ID: 21713601
[TBL] [Abstract][Full Text] [Related]
26. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
27. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively.
Bacci G; Picci P; Avella M; Dallari D; Ferrari S; Prasad R; Di Scioscio M; Malaguti C; Caldora P
J Chemother; 1990 Apr; 2(2):127-35. PubMed ID: 2362188
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
29. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities.
Bacci G; Picci P; Avella M; Ferrari S; Casadei R; Ruggieri P; Brach del Prevert A; Tienghi A; Battistini A; Mancini A
J Chemother; 1992 Jun; 4(3):189-95. PubMed ID: 1517815
[TBL] [Abstract][Full Text] [Related]
30. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
Winkler K; Bielack S; Delling G; Salzer-Kuntschik M; Kotz R; Greenshaw C; Jürgens H; Ritter J; Kusnierz-Glaz C; Erttmann R
Cancer; 1990 Oct; 66(8):1703-10. PubMed ID: 2208024
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
32. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup.
Lewis IJ; Weeden S; Machin D; Stark D; Craft AW
J Clin Oncol; 2000 Dec; 18(24):4028-37. PubMed ID: 11118463
[TBL] [Abstract][Full Text] [Related]
33. Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma.
Stine KC; Hockenberry MJ; Harrelson J; Miner D; Falletta JM
Cancer; 1989 Mar; 63(5):848-53. PubMed ID: 2914292
[TBL] [Abstract][Full Text] [Related]
34. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
[TBL] [Abstract][Full Text] [Related]
35. Impact of two cycles of preoperative chemotherapy with intraarterial cisplatin and intravenous doxorubicin on the choice of surgical procedure for high-grade bone sarcomas of the extremities.
Malawer M; Buch R; Reaman G; Priebat D; Potter B; Khurana J; Shmookler B; Patterson K; Schulof R
Clin Orthop Relat Res; 1991 Sep; (270):214-22. PubMed ID: 1884542
[TBL] [Abstract][Full Text] [Related]
36. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
[TBL] [Abstract][Full Text] [Related]
38. [The role of clinical and imaging criteria in risk assessment during preoperative chemotherapy for osteosarcoma].
Machak GN; Kochergina NV; Sen'ko OV; Kuznetsova AV
Vopr Onkol; 2005; 51(3):322-7. PubMed ID: 16279096
[TBL] [Abstract][Full Text] [Related]
39. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Bacci G; Ferrari S; Tienghi A; Bertoni F; Mercuri M; Longhi A; Fiorentini G; Forni C; Bacchini P; Rimondini S; De Giorgi U; Picci P
Eur J Surg Oncol; 2001 Feb; 27(1):98-104. PubMed ID: 11237499
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?
Bacci G; Picci P; Gherlinzoni F; Van Horn JR; Orlandi M; Normand AR; Manfrini M; Pignatti G; Campanacci M
Chemioterapia; 1986 Apr; 5(2):140-3. PubMed ID: 3458546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
